RMTG Expands to Puerto Rico with New Affiliate Partnership
Regenerative Medical Technologies Group (OTC:RMTG) has announced its expansion into Puerto Rico through a strategic partnership with Dr. Juan C. Ramos and Dr. Aleida G. Nieves, establishing Global Stem Cells Group Puerto Rico. The alliance follows RMTG's proven turnkey model, requiring six-figure upfront fees and exclusive supply agreements.
The expansion taps into Puerto Rico's $4.2 billion healthcare market and serves as a gateway to Latin American markets. RMTG reported strong Q1 2025 performance with sales of $1.35M, showing 67% growth year-over-year and operational profits of $134,000. The partnership adds to RMTG's global network of 26 clinics across 21 countries, with plans for a certified training center and local product distribution network.
Regenerative Medical Technologies Group (OTC:RMTG) ha annunciato la sua espansione a Porto Rico tramite una partnership strategica con il Dr. Juan C. Ramos e la Dr.ssa Aleida G. Nieves, fondando Global Stem Cells Group Puerto Rico. L'alleanza segue il collaudato modello turnkey di RMTG, che prevede costi iniziali a sei cifre e accordi di fornitura esclusivi.
L'espansione sfrutta il mercato sanitario di 4,2 miliardi di dollari di Porto Rico e rappresenta una porta d'accesso ai mercati latinoamericani. RMTG ha riportato un solido primo trimestre 2025 con vendite per 1,35 milioni di dollari, mostrando una crescita del 67% su base annua e profitti operativi di 134.000 dollari. La partnership arricchisce la rete globale di RMTG, che conta 26 cliniche in 21 paesi, con piani per un centro di formazione certificato e una rete locale di distribuzione dei prodotti.
Regenerative Medical Technologies Group (OTC:RMTG) ha anunciado su expansión en Puerto Rico mediante una asociación estratégica con el Dr. Juan C. Ramos y la Dra. Aleida G. Nieves, estableciendo Global Stem Cells Group Puerto Rico. La alianza sigue el modelo turnkey probado de RMTG, que requiere tarifas iniciales de seis cifras y acuerdos exclusivos de suministro.
La expansión aprovecha el mercado de salud de 4.2 mil millones de dólares de Puerto Rico y sirve como puerta de entrada a los mercados latinoamericanos. RMTG reportó un sólido desempeño en el primer trimestre de 2025 con ventas de 1.35 millones de dólares, mostrando un crecimiento del 67% interanual y ganancias operativas de 134,000 dólares. La asociación se suma a la red global de RMTG con 26 clínicas en 21 países, con planes para un centro de formación certificado y una red local de distribución de productos.
Regenerative Medical Technologies Group (OTC:RMTG)는 Dr. Juan C. Ramos 및 Dr. Aleida G. Nieves와의 전략적 파트너십을 통해 푸에르토리코에 진출하며 Global Stem Cells Group Puerto Rico를 설립했다고 발표했습니다. 이번 제휴는 RMTG의 검증된 턴키 모델을 따르며, 6자리 수 선불 비용과 독점 공급 계약을 요구합니다.
이번 확장은 푸에르토리코의 42억 달러 규모 의료 시장을 활용하며 라틴 아메리카 시장 진출의 관문 역할을 합니다. RMTG는 2025년 1분기에 135만 달러 매출과 전년 대비 67% 성장, 13만 4천 달러의 영업 이익을 기록하는 강력한 실적을 보고했습니다. 이번 파트너십은 21개국 26개 클리닉으로 구성된 RMTG의 글로벌 네트워크에 추가되며, 인증 교육 센터와 지역 제품 유통망 설립 계획도 포함되어 있습니다.
Regenerative Medical Technologies Group (OTC:RMTG) a annoncé son expansion à Porto Rico via un partenariat stratégique avec le Dr Juan C. Ramos et la Dre Aleida G. Nieves, établissant Global Stem Cells Group Porto Rico. Cette alliance suit le modèle clé en main éprouvé de RMTG, nécessitant des frais initiaux à six chiffres et des accords d'approvisionnement exclusifs.
L'expansion exploite le marché de la santé de 4,2 milliards de dollars de Porto Rico et sert de porte d'entrée aux marchés latino-américains. RMTG a rapporté une solide performance au premier trimestre 2025 avec des ventes de 1,35 million de dollars, affichant une croissance de 67% d'une année sur l'autre et des bénéfices opérationnels de 134 000 dollars. Le partenariat s'ajoute au réseau mondial de RMTG comprenant 26 cliniques dans 21 pays, avec des projets de centre de formation certifié et de réseau local de distribution de produits.
Regenerative Medical Technologies Group (OTC:RMTG) hat seine Expansion nach Puerto Rico bekannt gegeben, durch eine strategische Partnerschaft mit Dr. Juan C. Ramos und Dr. Aleida G. Nieves, und gründet Global Stem Cells Group Puerto Rico. Die Allianz folgt dem bewährten Turnkey-Modell von RMTG, das sechsstellige Vorauszahlungen und exklusive Lieferverträge erfordert.
Die Expansion nutzt den 4,2 Milliarden Dollar Gesundheitsmarkt von Puerto Rico und dient als Tor zu den lateinamerikanischen Märkten. RMTG meldete starke Ergebnisse im ersten Quartal 2025 mit Umsätzen von 1,35 Mio. Dollar, was einem Wachstum von 67% im Jahresvergleich und einem operativen Gewinn von 134.000 Dollar entspricht. Die Partnerschaft erweitert das globale Netzwerk von RMTG mit 26 Kliniken in 21 Ländern und plant ein zertifiziertes Ausbildungszentrum sowie ein lokales Produktvertriebsnetz.
- Q1 2025 sales reached $1.35M, representing 67% YoY growth
- Operational profits of $134,000 in Q1 2025
- New partnership generates immediate six-figure upfront fees plus recurring revenue
- Expansion into $4.2B Puerto Rico healthcare market with gateway to Latin America
- Addition to existing network of 26 clinics across 21 countries
- None.
Strategic Alliance Adds High-Value Territory to Global Network of 26 Clinics
LAS VEGAS, NV / ACCESS Newswire / July 21, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medical solutions, announces its official expansion into Puerto Rico through a newly formed alliance with Dr. Juan C. Ramos and Dr. Aleida G. Nieves at the new "Global Stem Cells Group Puerto Rico." The partnership was unveiled during a joint press conference led by GSCG's Founder Benito Novas, RMTG's CEO Dave Christensen, and the newly appointed representatives for Puerto Rico, Dr. Juan C. Ramos and Dr. Aleida G. Nieves, owners of Global Stem Cells Group Puerto Rico.
Financial Impact:
The Puerto Rico affiliate follows RMTG/GSCG's proven turnkey model, where new members pay upfront fees in the 6-figure dollar range plus ongoing special supply agreements. Led by Dr. Juan C. Ramos and Dr. Aleida G. Nieves, the partnership establishes Global Stem Cells Group Puerto Rico as a key strategic entry point into Caribbean and Latin American medical markets.
Strategic Partnership Benefits:
• Immediate Revenue Impact: New affiliates generate upfront fees, ongoing fees, plus ongoing exclusive purchases of RMTG's Cellgenic product line, creating both immediate and recurring revenue streams
• High-Value Market Entry: Puerto Rico's
• Proven Scalable Model: Partnership replicates RMTG's successful network framework used across 26 clinics in 21 countries, with turnkey setup reducing risk while ensuring consistent quality standards and brand recognition
• Comprehensive Support Infrastructure: New affiliate receives complete physician training through ISSCA's world-renowned education platform, ongoing clinical support, marketing assistance, and exclusive access to cutting-edge regenerative medicine protocols
• Strategic Geographic Positioning: Puerto Rico serves as gateway to Latin American markets while maintaining access to U.S. healthcare infrastructure, positioning RMTG for further Caribbean and Central American expansion
The partnership was announced during RMTG/GSCG's Buenos Aires press conference, where the Company hosted its ISSCA Argentina 2025 conference attracting over 200 medical professionals. Initial plans for Puerto Rico include development of a certified training center, local product distribution network, and the first ISSCA Puerto Rico event scheduled for December 2025.
"We are excited to welcome Dr. Juan C. Ramos and Dr. Aleida G. Nieves as our official representatives for Global Stem Cells Group Puerto Rico," said David Christensen, CEO and President. "We chose this location because of the extraordinary leadership and commitment we've seen in Dr. Juan C. Ramos, Dr. Aleida G. Nieves and their team at Global Stem Cells Group Puerto Rico. This alliance reflects our ongoing mission to bring regenerative medicine to every region where there is both need and readiness to embrace innovation."
The Puerto Rico expansion builds on RMTG's recent momentum, including Q1 2025 sales of
Dr. Juan C. Ramos and Dr. Aleida G. Nieves, who now lead the GSCG Puerto Rico operations, emphasized the impact this collaboration will have on the local medical landscape: "To have the official representation of Global Stem Cells Group in Puerto Rico is a major milestone for us - not just as a clinic, but as contributors to the future of medicine on the island," said Dr. Ramos. "We now have the opportunity to bring structured, science-based regenerative solutions to the physicians in Puerto Rico, backed by global expertise and a clear ethical framework."
Benito Novas, Founder of Global Stem Cells Group (GSCG), reflected on the significance of this new chapter: "This is more than just a representation agreement - this is a shared commitment to raising the standard of care in Puerto Rico. From day one, our organization has believed in forming alliances with visionary leaders who are ready to embrace the future of medicine. With Dr. Ramos and Dr. Nieves at Global Stem Cells Group Puerto Rico, we've found exactly that."
About RMTG:
RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company's affiliate program generates upfront membership fees in the six figure dollar range where new members receive turnkey assistance in setting up regenerative medicine clinics along with continuous training and support.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) serves as the dedicated educational and scientific arm of Global Stem Cells Group. ISSCA is a multidisciplinary, physician-led community composed of medical professionals, researchers, and scientists who are committed to advancing the clinical application of regenerative medicine and cellular therapies. The Society plays a pivotal role in bridging the gap between scientific research and clinical practice by providing a comprehensive platform for education, certification, and international collaboration. Through hands-on training programs, academic conferences, and ongoing professional development, ISSCA promotes the responsible, ethical, and evidence-based use of stem cell protocols across the globe. Its mission is to elevate standards of care and empower healthcare providers to deliver innovative regenerative solutions to their patients.
More information: https://www.issca.us/#
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is an international consortium of regenerative medicine entities encompassing clinics, laboratories, academic institutions, and product distributors. Headquartered in the United States, GSCG operates in more than 30 countries, offering a full-spectrum approach to the advancement of cellular medicine. The organization is dedicated to democratizing access to cutting-edge regenerative therapies by integrating scientific research, physician training, and high-quality product development. GSCG's initiatives are focused on improving patient outcomes while transforming the future of healthcare through innovation, strategic global partnerships, and a strong commitment to education. Its multifaceted infrastructure allows GSCG to support every stage of regenerative practice-from laboratory innovation to bedside application.
More information: www.stemcellsgroup.com or call +1 305 560 5331
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to its future revenues, affiliate partnerships, market expansion, or revenue generation from Puerto Rico operations. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Puerto Rico affiliate will achieve projected revenue targets, that market opportunities will materialize as anticipated, or that the affiliate model will continue to be successful. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price
For further information, please contact: investor.relations@regenmedtechgroup.com | (800) 956-3935
SOURCE: Regenerative Medical Technology Group
View the original press release on ACCESS Newswire
FAQ
What is RMTG's Q1 2025 revenue and growth rate?
How many clinics does RMTG operate globally in 2025?
What is the size of Puerto Rico's healthcare market that RMTG is entering?
How does RMTG's affiliate partnership model work?
Who are RMTG's new partners in Puerto Rico?
